UCB (BRSE:UNC) - Cours de l'action, nouvelles et analyse

UNC Aperçu des actions

A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. Plus de détails

UNC analyse fondamentale
Score flocon de neige
Évaluation	3/6
Croissance future	4/6
Performances passées	2/6
Santé financière	4/6
Dividendes	4/6

Récompenses

Se négocie à 46.8% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 24.84% par an

Analyse des risques

Les actions sont très illiquides

Les marges bénéficiaires (7.7%) sont inférieures à celles de l'année dernière (18.3%)

UCB SA Concurrents

Dottikon ES Holding

SWX:DESN

CHF 3.3b

Novartis

SWX:NOVN

CHF 183.8b

Roche Holding

SWX:ROG

CHF 204.1b

Cosmo Pharmaceuticals

SWX:COPN

CHF 1.0b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour UCB
Historique des cours de bourse
Prix actuel de l'action	€77.91
Plus haut sur 52 semaines	€0
Plus bas sur 52 semaines	€0
Bêta	0.33
1Variation sur 1 mois	0%
Variation sur 3 mois	n/a
Variation sur 1 an	n/a
3Variation sur 3 ans	n/a
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	-13.69%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	UNC	CH Pharmaceuticals	CH Marché
7D	0%	0.6%	0.5%
1Y	n/a	8.5%	6.3%

Rendement vs Industrie: Données insuffisantes pour déterminer la performance de UNC par rapport au secteur Swiss Pharmaceuticals.

Rendement vs marché: Données insuffisantes pour déterminer la performance de UNC par rapport au marché Swiss.

Volatilité des prix

Is UNC's price volatile compared to industry and market?
UNC volatility
UNC Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	2.8%
Market Average Movement	3.3%
10% most volatile stocks in CH Market	6.8%
10% least volatile stocks in CH Market	1.6%

Cours de l'action stable: UNC n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de UNC au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1925	8,406	Jean-Christophe Tellier	www.ucb.com

UCB SA Résumé des fondamentaux

Comment les bénéfices et les revenus de UCB se comparent-ils à sa capitalisation boursière ?
UNC statistiques fondamentales
Capitalisation boursière	CHF 16.10b
Bénéfices(TTM)	CHF 414.50m
Recettes(TTM)	CHF 5.38b

38.8x

Ratio P/E

3.0x

Ratio P/S

Le site UNC est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
UNC compte de résultat (TTM)
Recettes	€5.45b
Coût des recettes	€1.67b
Marge brute	€3.77b
Autres dépenses	€3.35b
Les revenus	€420.00m

Derniers bénéfices déclarés

Dec 31, 2022

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	2.22
Marge brute	69.27%
Marge bénéficiaire nette	7.71%
Ratio dettes/capitaux propres	30.5%

Quelles ont été les performances à long terme de UNC?

Voir les performances historiques et les comparaisons

Dividendes

1.5%

Rendement actuel des dividendes

60%

Ratio de distribution

Le site UNC verse-t-il des dividendes fiables ?

Voir UNC l'historique des dividendes et les indices de référence

Quand faut-il acheter UNC pour recevoir un dividende à venir ?
UCB dates des dividendes
Date ex-dividende	Apr 28 2023
Date de paiement du dividende	May 03 2023
Jours jusqu'au dividende Ex	579 days
Jours jusqu'à la date de paiement du dividende	574 days

Le site UNC verse-t-il des dividendes fiables ?

Voir UNC l'historique des dividendes et les indices de référence

UNC Aperçu des actions

Récompenses

Analyse des risques

UCB SA Concurrents

SWX:DESN

CHF 3.3b

SWX:NOVN

CHF 183.8b

SWX:ROG

CHF 204.1b

SWX:COPN

CHF 1.0b

Historique des prix et performances

Nouvelles et mises à jour récentes

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Recent updates

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

First half 2022 earnings released

Investor sentiment deteriorated over the past week

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results